Miliaria

01Pathophysiology

Miliaria develops from obstruction of the eccrine sweat glands, the primary thermoregulatory glands distributed across the body surface. When the sweat duct becomes blocked, secreted sweat cannot reach the skin surface and instead accumulates behind the point of obstruction. This trapped sweat eventually leaks into the surrounding epidermis or dermis, triggering an inflammatory response proportional to the depth of the blockage.

The obstruction itself results from a combination of factors. In neonates, the eccrine duct epithelium is structurally immature, making it prone to plugging. In adults, the mechanism involves keratin plugging of the sweat duct orifice (acrosyringium), often accelerated by maceration from prolonged moisture exposure, occlusive dressings, or bacterial biofilms (particularly from Staphylococcus epidermidis), which produce an extracellular polysaccharide substance that physically blocks the duct lumen.

The critical concept is that the depth of duct obstruction determines the clinical subtype. A very superficial block within the stratum corneum produces the mildest form (crystallina), because the trapped sweat sits just below the skin surface and causes virtually no inflammation. A mid-epidermal block (rubra) allows sweat to leak into the living epidermis, activating keratinocytes and triggering a pruritic inflammatory response. The deepest block at the dermal-epidermal junction (profunda) causes sweat to leak into the papillary dermis, resulting in deeper papules and, critically, a loss of functional sweating in the affected area. This is why miliaria profunda carries the risk of anhidrosis and heat intolerance, a clinically important complication that can progress to heat exhaustion in severe, widespread cases.

02Classification and Clinical Manifestation

An additional point worth noting: in neonates, miliaria crystallina is the most common subtype, often appearing within the first week of life, especially in infants kept in incubators or overwrapped. It is benign and self-limited.

03Diagnostic Workup

Miliaria is overwhelmingly a clinical diagnosis. The combination of a compatible exposure history (heat, humidity, occlusion, fever) with the characteristic morphology and distribution is sufficient. No laboratory or imaging studies are needed in routine cases.

When the presentation is atypical or when the rash fails to resolve with standard measures, a punch biopsy can confirm the diagnosis. Histopathology reveals sweat retention within the eccrine duct with surrounding spongiosis. In crystallina, the vesicle is subcorneal and inflammatory infiltrate is minimal. In rubra, there is spongiosis around the intraepidermal portion of the duct with a mixed inflammatory infiltrate. In profunda, the sweat duct rupture occurs at the dermal-epidermal junction, and infiltrate is deeper.

Bacterial culture of pustule contents should be obtained only in miliaria pustulosa to guide antibiotic selection if secondary staphylococcal infection is confirmed.

The main diagnostic task on an exam is not ordering tests but rather recognizing the clinical pattern and distinguishing it from other vesicular or papular eruptions.

04Management and Treatment

The cornerstone of treatment across all subtypes is removing the precipitating factor. Cooling the patient, reducing ambient humidity, and removing occlusive garments or dressings will resolve the majority of cases without pharmacological intervention. This is the "next best step" in virtually any exam question about miliaria.

For miliaria rubra with bothersome pruritus, topical corticosteroids are appropriate for short courses. Oral antihistamines may provide modest symptomatic relief but are not first-line because the itch in miliaria rubra is primarily driven by local inflammation rather than histamine release alone.

In neonates, the management principle tested most often is avoiding over-bundling. The instinct to wrap infants heavily should be countered by educating parents to dress the infant appropriately for the ambient temperature.

Miliaria profunda is the subtype with the most concerning complication. Because the sweat ducts are blocked at their deepest point, affected skin cannot thermoregulate. If this involves a large body surface area, the patient is at genuine risk for heat exhaustion or heat stroke, and management involves extended removal from hot environments until eccrine function recovers.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students miss miliaria questions is by confusing the subtypes and their depth of obstruction. A vignette describing a neonate in a warm nursery with asymptomatic, easily ruptured clear vesicles is crystallina, not rubra. A vignette describing flesh-colored, non-pruritic papules with subsequent exercise intolerance is profunda, not rubra. The test-writer is checking whether you understand that the clinical presentation maps directly to the anatomical depth of the blockage.

Another frequent trap involves the neonatal differential. When a newborn presents with a vesiculopustular eruption, students instinctively reach for infectious etiologies or erythema toxicum. The discriminator is the context: miliaria is triggered by excessive warming or occlusion, and the rash improves when the infant is cooled. Erythema toxicum, by contrast, is idiopathic and self-limited regardless of temperature changes, and its pustule smear shows eosinophils.

A third high-yield point: miliaria pustulosa is simply superinfected miliaria rubra, not a separate pathophysiological entity. When a vignette describes a patient with known prickly heat who now develops pustules, the answer is not to switch the diagnosis but to add antibiotic coverage while continuing environmental modification.

Finally, the core competency being tested is pattern recognition: the ability to link a common environmental trigger (heat, occlusion, immature ducts) to a characteristic rash morphology, classify it by subtype, and understand that the treatment is almost always removing the cause rather than reaching for pharmacotherapy.